About belantamab mafodotin
BCMA-directed antibody-drug conjugate
Used for
- Treats adults with relapsed or refractory multiple myeloma, in combination with other medicines, under applicable local approvals.
Usual adult dose
Usually 2.5 mg/kg by intravenous infusion every three weeks with bortezomib and dexamethasone; regimen varies by approval.
Common side effects
- Corneal changes and blurred vision
- Low platelet counts
- Anemia
- Infusion reactions
Important warnings
- Eye examinations are required before and during treatment; vision changes can be serious.
- Avoid driving or hazardous activities if vision is affected.
- Can cause severe low blood counts and infections.
- Pregnancy testing and effective contraception are required during treatment and afterward.
Pregnancy
May harm an unborn baby. Avoid during pregnancy; effective contraception is recommended during treatment and for four months after the last dose.
Breastfeeding
Breastfeeding is not recommended during treatment and for three months after the last dose.
Interactions
- No major established drug interactions; review all medicines with the treatment team.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.